Unmasking Anti‐ CASPR2 Syndrome in a Patient Treated for Myasthenia Gravis in the Era of New Treatments
European Journal of Neurology · 2025
DOI: 10.1111/ene.70285 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Vincent Fabry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Toulouse University Hospital, Toulouse Cedex 9, France. Hauptthemen laut MEDLINE: Myasthenia Gravis, Autoantibodies, Nerve Tissue Proteins, Membrane Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Myasthenia gravis (MG) is an autoimmune disorder characterised by autoantibodies against the acetylcholine receptor (AChR‐Ab). Morvan syndrome (MoS) is a rarer autoimmune disease with neuromyotonia, dysautonomia and encephalopathy, associated with antibodies targeting contactin‐associated protein‐like 2 (CASPR2) and may coexist with MG, particularly in patients with thymoma. Case Report A 57‐year‐old man with AChR‐Ab MG was treated with pyridostigmine and prednisone for one year and then presented with a severe exacerbation. The symptoms were not controlled despite intravenous immunoglobulins and plasmapheresis. Chest CT revealed a thymoma. Zilucoplan (a C5 complement inhibitor) was started, with rapid improvement. Efgartigimod (a neonatal Fc receptor (FcRn) antagonist) was added to stabilise residual symptoms prior to thymectomy. Three weeks after the third and final efgartigimod cycle, the patient had no symptoms of MG but began to develop profuse sweating, then generalised hypertonia, fasciculations, myoclonus and dysautonomia, consistent with MoS, which were confirmed by the presence of anti‐CASPR2 antibodies. Symptoms improved markedly after resumption of efgartigimod.
Conclusion
This case provides the first evidence of the efficacy of efgartigimod in the treatment of MoS and suggests that FcRn inhibition may be beneficial in IgG4‐mediated disorders beyond MG. It also highlights the importance of considering coexisting autoimmune conditions in thymoma, particularly when new symptoms occur under selective immune modulation. Finally, it emphasises the need to understand immunopathological mechanisms when choosing immunomodulatory treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Toulouse University Hospital, Toulouse Cedex 9, France.
- Department of Immunology, Federative Institute of Biology, Toulouse University Hospital, Toulouse Cedex 9, France.
- Department of Internal Medicine, Toulouse University Hospital, Toulouse Cedex 9, France.
ORCID-Profile: Vincent Fabry
Zitieren
APA
Fabry, V., Rual, C., Bost, C., Acket, B., Maquet, J., & Cintas, P. (2025). Unmasking Anti‐ CASPR2 Syndrome in a Patient Treated for Myasthenia Gravis in the Era of New Treatments. European Journal of Neurology. https://doi.org/10.1111/ene.70285
Vancouver
Fabry V, Rual C, Bost C, Acket B, Maquet J, Cintas P. Unmasking Anti‐ CASPR2 Syndrome in a Patient Treated for Myasthenia Gravis in the Era of New Treatments. European Journal of Neurology. 2025. doi:10.1111/ene.70285
BibTeX
@article{Fabry2025,
author = {Fabry, Vincent and Rual, Celso and Bost, Chloé and Acket, Blandine and Maquet, Julien and Cintas, Pascal},
title = {Unmasking Anti‐ CASPR2 Syndrome in a Patient Treated for Myasthenia Gravis in the Era of New Treatments},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70285}
}
EUVIMED